DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Higher stem cell dose may boost immune recovery after lymphoma treatment
Disease control OngoingThis study investigates whether giving a higher dose of a patient's own stem cells during transplant leads to better immune system recovery and outcomes for people with aggressive lymphoma that has returned or resisted treatment. Participants with relapsed or refractory diffuse l…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New Triple-Target immune cell therapy enters first human trial for tough blood cancers
Disease control ENROLLING_BY_INVITATIONThis is a first-in-human safety study testing a new, experimental CAR-T cell therapy called CAR19.20.22 in adults with B-cell lymphomas that have returned or not responded to at least two prior treatments. The therapy uses the patient's own immune cells, engineered to attack canc…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for Tough-to-Treat blood cancer
Disease control OngoingThis study is testing a new drug called purinostat mesylate for people with a type of aggressive blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or hasn't responded to previous treatments. The main goal is to find a safe and effective dose and see how…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
New combo therapy fights back against stubborn blood cancers
Disease control OngoingThis study is testing if adding the drug acalabrutinib to a personalized cell therapy (liso-cel) is safe and effective for adults with aggressive B-cell lymphomas that have come back or not responded to at least two prior treatments. Participants receive a one-time infusion of th…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Major trial aims to beat standard lymphoma treatment
Disease control OngoingThis large, late-stage study is comparing a new two-part drug called odronextamab combined with standard chemotherapy against the current standard treatment (rituximab + chemo) for people newly diagnosed with an aggressive blood cancer called diffuse large B-cell lymphoma (DLBCL)…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC